Cagrilintide is a once-weekly synthetic amylin analog, and the partner peptide in CagriSema, Novo Nordisk's next-generation obesity drug. Phase 2 monotherapy reported 9.7% mean body-weight reduction. With semaglutide, the pair reached 20.4% at 68 weeks in REDEFINE-1. It isn't FDA-approved as of May 2026.
The short answer. Cagrilintide is an amylin analog, not a GLP-1 agonist. It targets amylin receptors — the pathway engaged by the pancreatic hormone co-secreted with insulin.
- Phase 2 monotherapy (Lau et al., 2021): approximately 9.7% mean body-weight reduction reported at the 4.5 mg dose over 26 weeks, comparable to the liraglutide 3.0 mg active comparator.
- Phase III CagriSema (Garvey et al., 2025): 20.4% mean body-weight reduction at 68 weeks in REDEFINE-1, the largest pharmaceutical-magnitude readout reported at the time of publication.
- Not FDA-approved as of May 2026. Novo Nordisk regulatory filing is anticipated following Phase III completion.
Cagrilintide is a synthetic version of amylin. Amylin is a pancreas hormone. The body releases it with insulin at meals. A fatty-acid tail slows it down. That allows once-a-week dosing under the skin. Alone, Phase 2 cut body weight 9.7%. That ran over 26 weeks.
Paired with semaglutide it becomes CagriSema. REDEFINE-1 hit 20.4% at 68 weeks. That was the biggest figure on record then. Neither is FDA-approved as of May 2026. Novo Nordisk is expected to file. Retatrutide and tirzepatide are the closest compounds carried.
Quick orientation. Cagrilintide is the amylin component of CagriSema. Semaglutide is the GLP-1 component. Studies have tested the two together. The idea is that two distinct satiety pathways may add up. The pair may then beat either agent alone.
What cagrilintide actually is
Cagrilintide is a 37-amino-acid synthetic analog of human amylin. Amylin is a pancreatic hormone. The body puts it out with insulin at a meal. Novo Nordisk added a fatty-acid acyl chain to the structure. That chain binds albumin in the blood. Binding extends the half-life. A short-acting peptide becomes a once-weekly dosing candidate.
Native amylin presents two pharmacological challenges. It clears from the blood within minutes. It also tends to clump into amyloid fibers. That is the same clumping tied to type 2 diabetes pathology. Cagrilintide’s structural engineering addresses both. Getting there took roughly two decades of medicinal chemistry.
The development program runs two ways. Standalone cagrilintide is one track. The other track is CagriSema. That is a fixed-dose pairing with semaglutide. The combination has bigger Phase III numbers. So that is where the regulatory attention has gone. It is where most of our attention goes here too.
How it works
Amylin receptor binding
Cagrilintide binds the same receptors native amylin binds. That covers both central and peripheral sites. Preclinical and clinical studies report three things. Gastric emptying slows. Caloric intake drops. And post-prandial hepatic glucose output falls. All three fit amylin receptor activation.
It complements GLP-1
Why pair it with semaglutide? Amylin and GLP-1 both drive satiety. But they use overlapping, distinct brain circuits. A 2024 review by Melson and colleagues at the University of Leicester mapped that split. Hitting both gave additive satiety signaling in trial populations. It was not redundant.
Acylation and extended half-life
The fatty-acid tail does the same job here as in semaglutide and tirzepatide. Albumin binding is reversible. It extends how long the molecule stays in the blood. That allows once-weekly dosing. Acylation is now the standard way to turn fast-clearing peptides into long-acting drugs.
Dosing in clinical trials
Trial doses range from 0.3 mg to 4.5 mg weekly as monotherapy. In CagriSema, the dose is locked at 2.4 mg paired with 2.4 mg of semaglutide.
- Phase 2 monotherapy (Lau 2021): weekly subcutaneous doses of 0.3, 0.6, 1.2, 2.4, and 4.5 mg, starting at 0.3 mg and titrating up every four weeks. Compared against liraglutide 3.0 mg daily.
- REDEFINE-1 Phase III (Garvey 2025): cagrilintide 2.4 mg weekly, alone or with semaglutide 2.4 mg. 16-week titration, 68-week treatment.
- REDEFINE-2 (Davies 2025): same dosing in adults with type 2 diabetes and BMI 27 or higher.
The phased titration was protocol-specified in both the Phase 2 and REDEFINE-1 trials. Investigators noted that step-wise escalation was required to keep gastrointestinal adverse events within manageable bounds. It's the same titration rationale documented across semaglutide and tirzepatide trial designs.
Body-weight-reduction time course in trials
Published trial data reported a characteristic trajectory for cagrilintide across study arms. It matches the pattern seen in other long-acting incretin and amylin agents.
- Weeks 1–4 (titration phase): mean body-weight reduction of approximately 1–3% reported. Gastrointestinal adverse events peaked during this interval in trial data.
- Weeks 4–12: progressive body-weight reduction of approximately 4–7% as participants approached maintenance dose. GI event rates plateaued per trial reporting.
- Weeks 12–26: continued loss reaching approximately 9.7% at 26 weeks in Phase 2 monotherapy (4.5 mg arm, Lau et al., 2021).
- Weeks 26–68: attenuating rate of change. REDEFINE-1 reported cagrilintide monotherapy reaching ~11% and CagriSema reaching 20.4% at 68 weeks (Garvey et al., 2025).
Administration in clinical trials
Route and sites
In all published trials, cagrilintide was administered as a once-weekly subcutaneous injection. The REDEFINE-1 protocol specified rotation across standard subcutaneous sites: abdomen, thigh, upper arm. The third-party tested compound requires reconstitution. Novo Nordisk's anticipated commercial product should ship pre-formulated in an auto-injector.
Dose titration protocol
REDEFINE-1 used a 16-week titration schedule, escalating roughly every four weeks to reach the 2.4 mg maintenance dose. The Phase 2 trial by Lau and colleagues in 2021 also started at 0.3 mg with staged up-titration.
Investigators put the need for titration down to gastrointestinal tolerability. Adverse event rates ran markedly higher in earlier studies where titration was compressed.
CagriSema co-administration in REDEFINE-1
In REDEFINE-1, study participants in the CagriSema arm received cagrilintide 2.4 mg and semaglutide 2.4 mg as two separate subcutaneous injections administered on the same weekly schedule. Novo Nordisk has disclosed development of a co-formulated single-injection device, though this has not been reported in published trial data as of May 2026.
Research evidence summary
The evidence base here is unusual. Most peptides we cover have rodent papers and a handful of small human studies. Cagrilintide has two completed Phase III trials in NEJM, a Phase 2 trial in The Lancet, and a meta-analysis. We'd call that genuine pharmaceutical-grade evidence.
Phase 2 monotherapy — the Lau trial (2021)
The Phase 2 trial ran 26 weeks in 706 adults with obesity. Doses were 0.3, 0.6, 1.2, 2.4 and 4.5 mg weekly, plus liraglutide 3.0 mg as an active comparator and a placebo arm.
The headline: the highest cagrilintide dose hit 9.7% mean body-weight reduction, against 9.0% with liraglutide and 3.0% with placebo. The response was dose-dependent across all cagrilintide arms.
REDEFINE-1 — CagriSema in obesity without diabetes
REDEFINE-1 was a 68-week Phase III trial in 3,417 adults. Four arms: CagriSema, semaglutide alone, cagrilintide alone, and placebo. The CagriSema arm reported 20.4% mean body-weight reduction versus 3.0% for placebo. A significantly greater proportion of CagriSema study participants reached body-weight-reduction thresholds of 5%, 20%, 25%, and 30% compared with placebo.
REDEFINE-2 — CagriSema in type 2 diabetes
REDEFINE-2 investigated the same combination in 1,206 adults with type 2 diabetes. Mean weight change was −13.7% versus −3.4% with placebo. The glycemic endpoint was the primary headline: 73.5% of CagriSema study participants reached HbA1c at or below 6.5% versus 15.9% on placebo.
Meta-analysis
A 2024 systematic review by Dutta and colleagues aggregated the cagrilintide and CagriSema trials. Two findings stood out to us. The combination beat semaglutide alone by roughly 9 additional percentage points of body-weight reduction. And cagrilintide monotherapy showed significantly less vomiting than GLP-1 monotherapy, which suggests the high GI rate in CagriSema mostly comes from the semaglutide side.
Limitation in trial data. Gastrointestinal adverse event rates were substantial, and some commentators consider them underreported in industry communications. Approximately 80% of CagriSema participants in REDEFINE-1 reported some gastrointestinal symptom.
Most were classified as mild to moderate and transient. A subset were not. Trial investigators attributed the GI burden mostly to the semaglutide component, which fits the GLP-1 class profile.
The combination of cagrilintide and semaglutide produced significantly greater body-weight reduction than either component alone. That supports the rationale that engaging distinct satiety pathways yields additive efficacy in chronic obesity management.
— Paraphrased from Garvey et al., NEJM, 2025
CagriSema: dual-mechanism rationale
CagriSema is a fixed-dose pharmaceutical combination, not a self-assembled research protocol. The combination's pharmacological rationale is extensively documented in the trial literature, and we think it shows how the dual-mechanism incretin/amylin class operates.
Two satiety circuits. GLP-1 acts on hindbrain and hypothalamic satiety pathways. Amylin acts on overlapping but functionally distinct circuits within the same regions. Studies have reported additive rather than redundant satiety signaling when both pathways are engaged simultaneously.
Different tolerability profiles. The Dutta meta-analysis found cagrilintide monotherapy was associated with significantly less vomiting than GLP-1 monotherapy. This finding suggests cagrilintide monotherapy may represent a relevant research comparator for study cohorts in whom GLP-1 tolerability is a limiting factor.
Adjacent comparisons. The other multi-mechanism obesity drugs follow the same playbook: retatrutide, mazdutide and survodutide. We compare them all in our 2026 class comparison.
Side effects in trials
Commonly reported
- GI symptoms — nausea, vomiting, diarrhea, constipation, abdominal pain. 79.6% of CagriSema study participants in REDEFINE-1 reported some gastrointestinal symptom versus 39.9% on placebo. Trial reporting described most events as transient and mild-to-moderate.
- Injection-site reactions — redness, pain, or itching at the injection site, reported across trial arms.
- Reduced appetite and early satiety — consistent with the compound's amylin receptor mechanism; reported as an anticipated pharmacodynamic effect in trial documentation.
Less commonly reported
- Hypoglycemia — reported particularly in REDEFINE-2 study participants on background insulin or sulfonylureas. Rare in non-diabetic trial populations.
- Fatigue and dizziness — associated in trial reporting with the rate of body-weight reduction.
- Cholelithiasis — a class-level effect documented across rapid-body-weight-reduction pharmacotherapies.
Rare but serious
- Pancreatitis — theoretical class concern.
- Severe gallbladder disease — documented across the rapid-body-weight-reduction class.
- Allergic reactions — rare but reported across long-acting peptide products.
Legal status and FDA approval
As of May 2026:
- FDA (US): not approved as standalone or as CagriSema. Phase III is complete. Novo Nordisk filing is anticipated.
- EMA (EU): not approved.
- Pramlintide context: the short-acting amylin analog pramlintide (brand name Symlin) got FDA approval in 2005 as an insulin adjunct for diabetes. It's a different molecule, requires three to four shots a day, and isn't approved for the obesity indication.
Cagrilintide can be sold legally in the US as a research compound labeled for laboratory use only. Selling or marketing it for human therapeutic use is not legal before approval. You should also know that Novo Nordisk holds active patents on the molecule and its manufacturing chain.
Sports and WADA status
Cagrilintide hasn't been listed by name on the WADA Prohibited List. Two categories could apply on review:
- S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — as a peptide hormone analog, cagrilintide falls within S2's scope.
- S4 (Hormone and Metabolic Modulators) — the satiety and gastric-emptying effects also fit S4.
Check the current WADA Prohibited List directly for the authoritative categorization. Treat any unapproved investigational compound as high-risk for an inadvertent anti-doping violation if you're tested, whatever its formal status.
Frequently asked questions
What is cagrilintide?
Cagrilintide is a long-acting synthetic analog of amylin, the pancreatic hormone co-secreted with insulin in response to meals. Novo Nordisk engineered it for once-weekly subcutaneous dosing using fatty-acid acylation.
The two main development tracks are standalone monotherapy and the CagriSema fixed-dose combination with semaglutide. Neither has FDA approval as of May 2026, though two Phase III trials are published and a regulatory filing is anticipated.
How is cagrilintide different from CagriSema and from semaglutide?
These are three distinct entities. Cagrilintide is a single molecule, a long-acting amylin analog. Semaglutide is a separate molecule, a long-acting GLP-1 analog approved as Wegovy and Ozempic. CagriSema is the fixed-dose combination of both.
REDEFINE-1 reported the combination at 20.4% mean body-weight reduction, semaglutide alone at roughly 15%, and cagrilintide alone at roughly 11%. The combination beat either monotherapy arm on all pre-specified body-weight endpoints.
Is cagrilintide FDA-approved?
No. Neither standalone cagrilintide nor the CagriSema combination has received FDA approval as of May 2026. Phase III trial evidence has been published in NEJM. The molecule remains pre-approval and is sold in the US only as a research reference compound labeled for laboratory use only.
What does the monotherapy trial data show?
The Phase 2 trial by Lau and colleagues in 2021 tested doses from 0.3 to 4.5 mg weekly, against liraglutide 3.0 mg and placebo, over 26 weeks.
The 4.5 mg arm reported approximately 9.7% mean body-weight reduction. That's comparable to liraglutide's 9.0%, but with significantly less vomiting. In REDEFINE-1 at 68 weeks, the cagrilintide monotherapy arm reported approximately 11%.
How much does cagrilintide cost for research procurement?
No legitimate pharmacy price exists, because no standalone product has been approved. third-party tested vials from various suppliers in 2026 have listed at roughly $72–$200 per 5–10 mg vial, depending on purity tier and supplier.
Given the synthesis complexity of a 37-amino-acid acylated peptide, anything much below $60 per 5 mg vial should send you to independent identity and purity verification. Novo Nordisk's pharmaceutical-grade pricing on approval is expected in the Wegovy range, above $1,300 a month without insurance.
Where can research institutions source it?
Standalone cagrilintide is on the catalog roadmap pending Novo Nordisk's FDA review. For research on the multi-mechanism obesity class, the closest available alternatives are retatrutide, the GIP/GLP-1/glucagon triple agonist, and tirzepatide, the FDA-approved dual agonist.
When you evaluate any supplier, verify three specifications. HPLC purity at 98% or better. Mass-spectrometric confirmation of the acylated 37-residue molecule. And a CoA from an ISO/IEC 17025-accredited third-party laboratory.
How is cagrilintide different from pramlintide (Symlin)?
Both are amylin analogs, but they differ substantially in pharmacokinetics and clinical use. Pramlintide, FDA-approved as Symlin in 2005, is short-acting and needs an injection with each meal, typically three or four a day. It's approved as a diabetes adjunct to insulin.
Cagrilintide is a long-acting, fatty-acid-acylated formulation designed for once-weekly dosing, developed mainly for obesity rather than glycemic control. The acylation engineering, and the half-life extension it buys, is the key structural and clinical distinction.
What to know now
- Cagrilintide is an amylin analog, not a GLP-1 agonist. It targets amylin receptors — the pathway engaged by the pancreatic hormone co-secreted with insulin.
- Phase 2 monotherapy (Lau et al., 2021): approximately 9.7% mean body-weight reduction reported at the 4.5 mg dose over 26 weeks, comparable to the liraglutide 3.0 mg active comparator.
- Phase III CagriSema (Garvey et al., 2025): 20.4% mean body-weight reduction at 68 weeks in REDEFINE-1, the largest pharmaceutical-magnitude readout reported at the time of publication.
- Not FDA-approved as of May 2026. Novo Nordisk regulatory filing is anticipated following Phase III completion.
- Gastrointestinal adverse events were substantial in trial data. Approximately 80% of CagriSema study participants in REDEFINE-1 reported some gastrointestinal symptom; trial investigators attributed most of this burden to the semaglutide component.
- Distinct from pramlintide. Pramlintide is a short-acting amylin analog approved for diabetes insulin-adjunct use; cagrilintide is a long-acting formulation developed for obesity pharmacotherapy.
What we’re watching
Novo Nordisk's regulatory filing timeline is the primary watch-item. Approval, anticipated in 2026–2027 pending review, would move cagrilintide from research reference compound to FDA-regulated therapeutic. That changes the regulatory and commercial landscape substantially.
The split between standalone cagrilintide and CagriSema development tracks is also worth following. Monotherapy may suit study populations where GLP-1 tolerability is the limiting factor, while the combination targets the highest-magnitude efficacy segment.
The co-formulated single-injection CagriSema device hasn't appeared in published trials as of May 2026. Its development status has implications for trial logistics and co-administration research design.
What people actually report
These are self-reports, not evidence. No control group, no blinding, and no independent check that the vial held what the label claimed. They are collected here because people asking about Cagrilintide deserve an answer rather than a refusal, and because what the community believes is itself worth knowing. Quotes are excerpts; each links to the original post.
These are uncontrolled self-reports, and the first thing they show is a stacking problem: five of the six sources here run cagrilintide on top of tirzepatide or retatrutide rather than alone, so almost nothing described can be assigned to cagrilintide by itself. Within that limit the reports do not converge. u/mooswi on r/Retatrutide, about a month into retatrutide, adds cagrilintide and writes that the smell, thought and sight of food are nauseating and that they have not eaten in almost five days; the same post calls the peptide incredibly intense and tells readers not to take it. u/Practical-Object-818, already maxed out on tirzepatide, reports feeling nothing on the day of the shot or the day after, then waking nauseous and drained. u/Significant-Gap6571 reports the opposite problem: 0.25 did nothing, 0.50 did nothing, and only 1mg registered. u/Due_University5083 reports constipation bad enough to stop for good, and no calming of food noise. Two of the six are creator videos whose descriptions link to paid coaching or a paid course. Nothing here is controlled, blinded, or checked against a lab result on the vial.
Where the community and the published record disagree. Five of the six self-reports here run cagrilintide on top of tirzepatide or retatrutide. A ClinicalTrials.gov query for cagrilintide as an intervention returns 43 registered studies, and not one of them gives cagrilintide together with either drug. Tirzepatide appears in exactly three, and in all three it is what CagriSema is measured against rather than something added to it: NCT06131437, NCT06221969 and NCT06534411 are all titled as CagriSema compared to tirzepatide. Retatrutide appears in none of the 43. The combination the registry has actually tested is cagrilintide with semaglutide, which is CagriSema, in 34 of the 43. One trial does co-dose cagrilintide with something other than semaglutide, Novo Nordisk's NCT07411560, which pairs it with GIP to study stomach side effects. The stack the community reaches for first is the one its own evidence base has never run.
“I have not eaten for almost 5 days now, genuinely.”
“Today I wake up feeling nauseous and just drained.”
“So started at 0.25 nothing. Tried 0.50 nothing.”
“I didn't notice any calming of food noise”
Comment on: Information about Cagrilintide. How did it work for you? Side effects?
“Serotonin Connection: Why Cagrilintide Can Make You Feel Down”
My Honest Cagrilintide Experience: Side Effects, Benefits & Best Dose
“becoming one of the most talked-about combinations for appetite suppression, cravings, and fat loss”
Retatrutide + Cagrilintide: The STRONGEST Appetite Suppression Stack?!
Posts are quoted under fair use and linked to their authors. Nothing on this page is hosted here, and no claim above has been verified beyond confirming that the person wrote it.
References
- Lau, D. C. W., Erichsen, L., Francisco, A. M., Satylganova, A., le Roux, C. W., McGowan, B., Pedersen, S. D., Pietiläinen, K. H., Rubino, D., & Batterham, R. L. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet, 398(10317), 2160–2172. https://doi.org/10.1016/S0140-6736(21)01751-7
- Garvey, W. T., Blüher, M., Osorto Contreras, C. K., et al. (2025). Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New England Journal of Medicine, 393(7), 635–647. https://doi.org/10.1056/NEJMoa2502081
- Davies, M. J., Bajaj, H. S., Broholm, C., et al. (2025). Cagrilintide–semaglutide in adults with overweight or obesity and type 2 diabetes. New England Journal of Medicine, 393(7), 648–659. https://doi.org/10.1056/NEJMoa2502082
- Dutta, D., Nagendra, L., Harish, B. G., et al. (2024). Efficacy and safety of cagrilintide alone and in combination with semaglutide (CagriSema) as anti-obesity medications: A systematic review and meta-analysis. Indian Journal of Endocrinology and Metabolism, 28(5), 436–444. https://doi.org/10.4103/ijem.ijem_45_24
- Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2024). What is the pipeline for future medications for obesity? International Journal of Obesity, 49(3), 433–451. https://doi.org/10.1038/s41366-024-01473-y
- World Anti-Doping Agency. (2026). The Prohibited List. https://www.wada-ama.org/en/prohibited-list
- International Organization for Standardization. (2017). ISO/IEC 17025:2017 — General requirements for the competence of testing and calibration laboratories. https://www.iso.org/standard/66912.html